Inspira Technologies Oxy B.H.N. Ltd. (IINN)
| Market Cap | 24.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.29M |
| Shares Out | 18.50M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,273 |
| Open | 1.290 |
| Previous Close | 1.280 |
| Day's Range | 1.250 - 1.327 |
| 52-Week Range | 0.761 - 2.490 |
| Beta | 2.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 15, 2024 |
About IINN
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of proprietary life support technology for the treatment of acute respiratory failure. Its lead product is the INSPIRA augmented respiration technology (Gen 2) device, a life support designed to provide Adaptive Blood Oxygenation that to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd.... [Read more]
Financial Performance
Financial StatementsNews
Join Inspira™ Technologies' Live Investor Webinar and Q&A Session on November 11
RA'ANANA, Israel, Nov. 8, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the life supp...
Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100
The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and customer support center in the U.S. RA'ANANA, Israel , Oct. 24, 2024 /PRNewswire/ ...
Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism
RA'ANANA, Israel , Oct. 9, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking respiratory s...
Inspira™ Launches INSPIRA™ ART100 at the World's Largest Extracorporeal Life Support Conference
RA'ANANA, Israel , Sept. 24, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.
Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System
To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with...
Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024
The clip-on HYLA™ blood sensor, designed to alert physicians of immediate signs of changes in a patient's clinical condition without the need for intermittent actual blood samples, targets a potential...
Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product
RA'ANANA, Israel , Aug. 22, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, toda...
Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow
RA'ANANA, Israel , Aug. 13, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a trailblazer in life-suppor...
Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest
Inspira's innovation targets life-saving intervention for patients with cardiac arrest, of which there are approximately 550,000 annual cardiac arrest events in the U.S., including 350,000 outside hos...
Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System
Approval follows the FDA clearance announced on May 28, 2024 RA'ANANA, Israel , July 11, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "I...
Inspira™ Announces Business Plan Targets
Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel , June ...
Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel
RA'ANANA, Israel , June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology compa...
Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in the U.S.
First units expected to be shipped in Q4 2024. The Purchase Order follows the recent FDA Clearance of the INSPIRA™ ART100.
Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector
The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel , June 5, 2024 /PRNewswire/ -- Inspira™ Technologies...
Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments
RA'ANANA, Israel , May 30, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira") a breakthrough medical technology company, announced today that...
INSPIRA™ ART100 Receives FDA 510(k) Clearance
RA'ANANA, Israel , May 28, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company", "Inspira", or "Inspira Technologies"), a breakthrough medical techn...
Inspira™ Announces Start of Production of the INSPIRA™ ART100
RA'ANANA, Israel , May 2, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced the start ...
Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100
RA'ANANA, Israel , April 25, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announce...
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
RA'ANANA, Israel , April 16, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is proud...
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
RA'ANANA, Israel , April 10, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, together...
Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb
RA'ANANA, Israel , April 3, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is deligh...
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager
RA'ANANA, Israel , April 1, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), today announced a strategic investment by leading investor, Mr...
Inspira™ Technologies Reports Full Year 2023 Financial Results
FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel...
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
RA'ANANA, Israel , March 18, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is excited to ann...
Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator
An unprecedented achievement of a zero pressure gradient measured when using the VORTX™ device, directly correlating with a decrease in markers of blood damage. The performance of the VORTX™, tested a...